Get a Quote
Skip to main content

Tacrolimus pharmacokinetics: the low-dose genotype problem

Tacrolimus pharmacokinetics swing several-fold between kidney transplant recipients on identical weight-based doses, and three ABCB1 variants explain part of that spread. In 383 recipients followed for five years, the rs2032583 TT genotype produced higher concentration-to-dose ratios and lower dose requirements. The same genotype carried a 2.17-fold relative risk of BK viremia and a 1.50-fold relative risk of cytomegalovirus viremia.

That pairing is the whole point. The genotype that lets a patient get away with a smaller dose is also the genotype that picks up more viral complications. Anyone reading trough levels alone would see adequate exposure all day long and never suspect a thing, because the problem is not the number on the assay. It is how much drug the tissue actually sees.

Now flip it. The other end of the spectrum, rs1045642 CC, needed more drug to hit the same trough and turned up with more biopsy-proven calcineurin inhibitor toxicity, a 50 percent fall in estimated glomerular filtration rate and a trend toward graft loss. Two variants, two failure modes, and one assay that cannot tell them apart.

Why tacrolimus pharmacokinetics still surprises transplant teams

Tacrolimus has a narrow window, unpredictable oral bioavailability, and a dose requirement that moves with food, diarrhea, anemia and every interacting drug on the list. Therapeutic drug monitoring handles the last mile, but it measures a trough in whole blood rather than exposure inside a lymphocyte.

Transporter biology explains part of the gap. ABCB1 encodes P-glycoprotein 1, an ATP-dependent efflux pump on enterocytes, hepatocytes and renal tubular cells. It pushes tacrolimus back into the intestinal lumen and caps how much reaches the circulation. The gene is highly polymorphic, and the three variants below have been studied for two decades with contradictory results, partly because cohorts differ in size, ancestry and background immunosuppression.

There is a practical reason to keep revisiting it. Genotype-guided dosing already exists for CYP3A5, where expressors need roughly double the dose to reach the same trough. If ABCB1 carried comparable information, it would belong on the same pre-transplant panel. If it does not, the field needs a clean negative to stop re-testing.

How the 383-recipient cohort was genotyped

Single center, retrospective, adults transplanted across five years and maintained on tacrolimus, with a mean five-year follow-up.

Item

Detail

Design

Single-center retrospective cohort

Recipients

383 adult kidney allograft recipients

Transplant window

January 2011 to December 2015

Follow-up

Mean 5 years

Variants genotyped

ABCB1 rs1045642, rs2032582, rs2032583

Target trough, first 3 months

6 to 8 ng/mL

Target trough, after 3 months

5 to 7 ng/mL

Monitoring method

Chemiluminescent microparticle immunoassay on whole blood

Exposure metric

Concentration-to-dose ratio over the first 6 months

Deceased donors

274 (72 percent)

Preformed anti-HLA antibodies

148 (39 percent)

Interleukin-2 receptor antagonist induction

359 (94 percent)

Anti-thymocyte globulin induction

20 (5 percent)

Mycophenolate mofetil or mycophenolic acid

334 (87 percent)

Anti-CMV IgG positive

219 (57 percent)

Genotype frequencies looked like a European transplant population. For rs1045642, 284 recipients (74 percent) carried TT or TC and 99 carried CC. For rs2032582, 311 carried GG, GT or GA against 70 with TT or TA. For rs2032583, 291 carried TT and 90 carried TC or CC.

The exposure metric is why the study can say anything quantitative about tacrolimus pharmacokinetics at all. Concentration-to-dose ratio divides a measured trough by the daily dose that produced it, normalizing for dose and converting every routine drug level into a phenotype. A patient with a ratio of 4 needs half the dose of a patient with a ratio of 2 to sit at the same concentration. Cheap, high-resolution, and built from data the clinic already generates.

Which genotypes actually shift tacrolimus pharmacokinetics

One variant moved exposure convincingly. One moved it modestly. One did nothing.

Variant

Genotype comparison

Effect on concentration-to-dose ratio

Interpretation

rs2032583

TT versus C-allele carriers

Significantly higher ratio in TT during the first 6 months

Strongest pharmacokinetic signal in the study

rs1045642

TT or TC versus CC

Higher ratio in TT or TC carriers

Modest, consistent with prior reports

rs2032582

GG, GT or GA versus TT or TA

No difference in the first 6 months

No pharmacokinetic effect detected

The rs2032583 result carries the weight, because it landed in the direction transporter biology predicts. The T allele at that position has been linked to lower P-glycoprotein expression, less efflux from gut and liver, and therefore higher systemic exposure per milligram. Higher ratio, lower dose requirement, more drug in the blood.

The rs1045642 result is weaker and messier, which fits a literature that has argued about it for years. Some cohorts report higher ratios in T-allele carriers, some report the reverse, several report nothing. A modest effect in 383 patients does not settle that argument.

The rs2032582 null earns its keep. A clean negative on a well-powered variant says the transporter story is not a generic property of every ABCB1 polymorphism, which is precisely the assumption that made earlier studies disagree.

Viral complications follow the genotype, not just the trough

This is where the paper starts to matter, because the clinical associations point the same way as the pharmacokinetics instead of against it.

Variant and genotype

CMV viremia

BK viremia

BKV-associated nephropathy

rs1045642 TT or TC versus CC

40 percent versus 27 percent, RR 1.46 (1.04 to 2.01), P = 0.03

25 percent versus 17 percent, RR 1.45, P = 0.13

7 percent versus 4 percent, P = 0.34

rs2032582 TT or TA versus GG, GT or GA

44 percent versus 35 percent, RR not significant

33 percent versus 21 percent, RR 1.57 (1.04 to 2.30), P = 0.04

11 percent versus 5 percent, RR 2.22, P = 0.06

rs2032583 TT versus TC or CC

RR 1.50 (1.05 to 2.19), P = 0.02

RR 2.17 (1.24 to 3.91), P = 0.004

Trend only, P = 0.08

Across the whole cohort, 140 recipients (37 percent) developed cytomegalovirus viremia, 89 (23 percent) BK viremia and 24 (6 percent) BK-associated nephropathy. Seven (2 percent) had herpes simplex infection and 73 (19 percent) Epstein-Barr infection, so the burden is not spread evenly across the herpesvirus family.

Survival analyses put time into the picture. Cytomegalovirus-free survival was significantly worse for rs1045642 TT or TC carriers (P = 0.01) and for rs2032583 TT carriers (P = 0.02). BK viremia-free survival was worse for rs2032583 TT carriers (P = 0.008) and for rs2032582 TT or TA carriers (P = 0.02), with nephropathy-free survival reduced in the same group (P = 0.05).

One caveat for anyone who reads risk estimates for a living: these effect sizes sit between 1.5 and 2.2, and several intervals reach nearly to 1. Associations in one cohort, not risk strata that justify a new monitoring schedule by themselves.

BK virus separates the three variants most sharply

Cytomegalovirus associations mostly track the pharmacokinetic signal, which is what you expect if more exposure means deeper immunosuppression. BK virus does something more interesting. It separates a genotype that the concentration-to-dose ratio could not separate at all.

The rs2032582 TT or TA genotype had no effect on tacrolimus pharmacokinetics, yet carried the highest BK viremia risk in the study at 33 percent against 21 percent, relative risk 1.57, with a nephropathy signal of 2.22 that just missed significance at P = 0.06. A variant that changes no measurable drug level but changes infection risk is pointing somewhere other than systemic exposure.

Two explanations exist. P-glycoprotein sits on T lymphocytes, and those are exactly the cells that control BK replication, so a transporter variant could shift intracellular drug concentrations in the compartment that matters while leaving whole-blood troughs untouched. Or the variant rides in linkage with an immune locus nobody measured. Neither can be tested here, and the honest position is that the mechanism is open.

The combination analysis adds a third layer. Carrying rs2032583 TT together with rs2032582 TT or TA cut BK viremia-free and nephropathy-free survival more than either variant alone, while other pairings and the full three-variant combination added nothing. That is what two partly independent mechanisms look like, and it argues against treating ABCB1 as one dial.

Allograft function moves the other way

Nephrotoxicity runs opposite to infection, and the inversion is the most useful thing in the paper.

Outcome

Genotype with the higher risk

Estimate

P value

Biopsy-proven calcineurin inhibitor toxicity

rs1045642 CC

Higher than TT or TC carriers

Reported as significant

Estimated GFR fall greater than 50 percent

rs1045642 CC

RR 1.67 (1.11 to 2.49)

0.02

Allograft failure

rs1045642 CC

RR 1.72 (1.003 to 2.91)

0.054

Rejection or de novo donor-specific antibodies

No genotype

No association detected

Not significant

So the CC genotype at rs1045642 needed more drug to reach target, and collected more drug-related kidney damage on the way. The TT or TC genotype needed less, ran higher exposure per milligram, and paid in viral infections instead. Neither is protective. They fail differently.

The flat rejection result matters as much as the positive ones. If ABCB1 genotype were just a proxy for immunosuppressive intensity, the under-exposed CC group should have generated more alloimmune injury. It did not. The likely reason is that trough-guided adjustment corrected the exposure difference well enough to protect against rejection while leaving intracellular and tissue-level differences untouched.

Where mycophenolate mofetil fits into the exposure story

Almost nobody in this cohort was on one drug. Three hundred and thirty-four recipients (87 percent) received mycophenolate mofetil or mycophenolic acid alongside tacrolimus, which is the standard maintenance pairing in kidney transplantation and the context in which any tacrolimus finding has to be read.

Three consequences follow. First, mycophenolate mofetil exerts independent antiviral pressure by blocking inosine monophosphate dehydrogenase and suppressing lymphocyte proliferation, and the mycophenolate dose is a recognized lever when cytomegalovirus or BK viremia appears. Second, mycophenolate exposure varies widely and is usually left unmonitored in favor of tacrolimus troughs, so a cohort adjusting only tacrolimus may credit tacrolimus for something the antimetabolite did. Third, both drugs compete for one decision at the bedside: when viremia shows up, which agent comes down first.

For a formulation supplier the implication is unglamorous and real. Mycophenolate mofetil is dosed in fixed milligrams with no routine therapeutic drug monitoring, so its performance rests entirely on the consistency of the finished oral product: assay content, dissolution behavior, batch-to-batch uniformity. A tacrolimus exposure study measures a monitored drug. The unmonitored partner has no such safety net, and there manufacturing consistency substitutes for clinical feedback.

The counterintuitive part: less drug, more infection

The headline reads backwards until dose and exposure are separated. RS2032583 TT carriers needed lower doses, achieved higher concentration-to-dose ratios, and developed more cytomegalovirus and BK viremia.

The resolution is that the ratio measures blood, and the compartment that matters is not blood. If P-glycoprotein is scarcer in the gut and liver of TT carriers, more tacrolimus enters the circulation per milligram, the trough rises and the prescriber cuts the dose. But the same reduced efflux may act in lymphocytes, where tacrolimus must be pumped out or held to set the intracellular concentration that actually inhibits calcineurin. A patient can therefore show a comfortable trough, a modest dose, and a locally over-suppressed lymphocyte compartment.

That reading also explains the odd rs2032582 result, where no systemic pharmacokinetic signal coexisted with the strongest BK association. Variants that act inside a tissue compartment leave no fingerprint on a blood assay, which is exactly why trough monitoring feels reassuring and sometimes is not.

A mundane alternative deserves equal space. Patients with high ratios may simply be carrying more drug than intended because dose changes lag measured levels, and that excess does the immunological damage. Under that reading the genotype marks how often the prescriber was behind the curve rather than acting as a direct cause. These data cannot separate the two, and both produce the same tables.

What a transplant pharmacist should do with this

Nothing here justifies genotype-guided tacrolimus dosing today. What it justifies is a different reading of data already on the chart.

Observation

Reasonable response

What to avoid

Patient needs an unusually low dose to hold a therapeutic trough

Recognize possible overexposure at tissue level and review total immunosuppression

Assuming low dose means light immunosuppression

Persistent BK viremia despite acceptable troughs

Treat troughs as incomplete evidence and consider reducing the antimetabolite

Escalating tacrolimus because viremia is assumed to reflect under-immunosuppression

Rising cytomegalovirus viral load with stable levels

Review mycophenolate mofetil dose and prior valganciclovir prophylaxis strategy

Increasing tacrolimus as a reflex response

New creatinine rise with a stable trough

Consider calcineurin inhibitor toxicity, particularly in rs1045642 CC carriers

Attributing allograft dysfunction to rejection without histology

Repeated dose escalation to hit a target trough

Check whether the ratio is unusually high before escalating further

Chasing a number that may already represent excess exposure

The fourth row is where the data bite. Genotype influenced nephrotoxicity and graft function but never rejection, which suggests routine dose adjustment was good at preventing alloimmunity and less good at preventing chronic drug toxicity. Any patient with a slowly rising creatinine and a normal trough deserves both possibilities kept open.

Limitations worth stating plainly

One center, one European genotype distribution, five transplant years and a five-year mean follow-up, during which practice patterns moved and cytomegalovirus prophylaxis strategies went unrecorded.

CYP3A5 genotype was not co-modeled, even though it is the dominant pharmacogenetic determinant of tacrolimus dose requirement and is known to interact with outcomes. Without it, the ABCB1 effects here are partly confounded by an unmeasured variable sitting upstream of the same phenotype. Mycophenolate dose and exposure were equally absent.

Clinical events came from routine records rather than protocolized screening, so viremia detection depends on how often each clinician ordered a viral load. Several estimates sit at the boundary, including a graft loss risk whose interval starts at 1.003 and a nephropathy association at P = 0.06, and none of it survives correction across three variants and five outcomes.

Bottom line

ABCB1 genotype shifts tacrolimus pharmacokinetics enough to change dose requirements, and more importantly enough to change which complication a patient is likely to meet. RS2032583 TT carriers run higher concentration-to-dose ratios on lower doses and carry a 2.17-fold relative risk of BK viremia and 1.50-fold for cytomegalovirus. RS1045642 CC carriers need more drug and show more calcineurin inhibitor toxicity and graft function loss. Trough monitoring sees neither pattern, so a normal level in a patient with unexplained viremia or a rising creatinine deserves a second thought rather than reassurance.

FAQ

What does ABCB1 genotype actually change about tacrolimus?

It changes how much drug reaches the bloodstream for a given milligram dose. ABCB1 encodes P-glycoprotein 1, an efflux pump in the gut wall, liver and kidney that pushes tacrolimus back out of cells and limits absorption. Variants that reduce pump expression raise systemic exposure, which shows up as a higher concentration-to-dose ratio and a lower dose requirement. The strongest signal in this cohort came from rs2032583, with rs1045642 showing a smaller effect and rs2032582 showing none at all.

Should tacrolimus dosing be guided by ABCB1 genotype now?

Not on the basis of this evidence. The associations are moderate in size, come from a single retrospective cohort, and were not adjusted for CYP3A5 genotype, which remains the dominant pharmacogenetic determinant of dose requirement. Genotype-guided dosing for CYP3A5 has prospective trial support and is already used in some centers. ABCB1 genotyping would currently add interpretation without adding a validated dose algorithm, so trough monitoring with clinical judgment remains the standard.

Why would a patient on a low tacrolimus dose get more infections?

Because the dose is not the exposure. A patient who needs only 2 mg daily to reach a target trough may be absorbing a far larger fraction of each milligram than a patient who needs 8 mg. If the efflux pump is less active in gut and liver, blood levels rise and the prescriber reduces the dose, but the same reduced pumping may operate in lymphocytes, leaving a higher intracellular drug concentration in the cells that control cytomegalovirus and BK virus. The blood assay reports the dose adjustment, not the compartment that matters.

Which virus is most strongly linked to ABCB1 variants?

BK virus separated the genotypes most sharply in this cohort. The rs2032583 TT genotype carried a relative risk of 2.17 for BK viremia, the largest effect reported, and worse BK viremia-free survival at P = 0.008. Cytomegalovirus associations were smaller, at 1.46 to 1.50 across variants. BK-associated nephropathy trends followed the same pattern but did not always reach significance, with P values of 0.05 and 0.06 in the strongest comparisons.

Does the same genotype protect the kidney from toxicity?

It appears to, at the cost of more infection. The rs1045642 CC genotype required higher doses to reach target troughs and had more biopsy-proven calcineurin inhibitor toxicity, a relative risk of 1.67 for a greater than 50 percent fall in estimated glomerular filtration rate, and a relative risk of 1.72 for allograft failure that narrowly missed significance. The trade-off is real: the genotype that protects against drug toxicity in this dataset is the one that carries more viral complications.

Why did rejection not differ between genotypes?

Probably because trough-guided dosing corrected the exposure gap well enough to protect against alloimmunity. Rejection and de novo donor-specific antibody formation showed no association with any of the three variants. If ABCB1 were a simple proxy for overall immunosuppressive intensity, the low-exposure genotype should have shown more rejection. The absence of that signal suggests that dose adjustment handles the blood compartment competently while leaving tissue-level differences unaddressed.

How common are these viral complications after kidney transplant?

In this cohort, 37 percent of recipients developed cytomegalovirus viremia and 23 percent BK viremia over five years, with BK-associated nephropathy in 6 percent. Epstein-Barr infection appeared in 19 percent and herpes simplex in 2 percent. Those rates reflect an era-specific prophylaxis policy and a single center's monitoring habits, so they should not be transplanted to another program without checking local cytomegalovirus serostatus mix and valganciclovir prophylaxis duration.

What should be done when BK viremia appears on a stable tacrolimus level?

The first move is usually to reduce total immunosuppression rather than to escalate it. In practice that means cutting the antimetabolite, which in 87 percent of this cohort was mycophenolate mofetil or mycophenolic acid, before touching the calcineurin inhibitor. The genotype data add a reason for caution about the reverse strategy: if a patient is already a high-exposure genotype, raising tacrolimus to suppress a virus that thrives under immunosuppression is unlikely to help and may add nephrotoxicity.

Can a combination of variants predict risk better than one?

Only one pairing did. Combining rs2032583 TT with rs2032582 TT or TA produced a stronger reduction in BK viremia-free and nephropathy-free survival than either variant alone, which is consistent with two partly independent mechanisms. Other pairings, including the combination of all three variants, added nothing beyond the single variants. That pattern argues against building a multi-variant risk score from these data.

What are the main limitations of this study?

It is single-center and retrospective, with genotype frequencies specific to one population and practice patterns that shifted across a five-year transplant window. CYP3A5 genotype and mycophenolate exposure were not modeled, so the ABCB1 estimates carry unmeasured confounding from the dominant pharmacogenetic pathway. Viral events depended on clinician-initiated testing, several estimates sit near the significance boundary, and nothing here survived correction for the number of comparisons tested.

Does mycophenolate mofetil dose affect these viral outcomes?

It plausibly does, and this study could not measure it. Mycophenolate mofetil or mycophenolic acid was used in 87 percent of recipients, and antimetabolite reduction is the standard first response to cytomegalovirus or BK viremia. Because mycophenolate has no routine therapeutic drug monitoring, its exposure was neither recorded nor adjusted in the models, which means some of what is attributed to tacrolimus pharmacokinetics may belong to the unmeasured partner drug.

How should a rising creatinine be interpreted in a stable patient?

As ambiguous, and worth investigating rather than treating empirically. In this cohort, genotype predicted calcineurin inhibitor toxicity and graft function decline but never rejection, which means a rising creatinine on a therapeutic trough could be drug toxicity rather than alloimmunity. Biopsy remains the discriminator. Escalating immunosuppression on the assumption of rejection risks worsening the very nephrotoxicity that may be causing the problem.